GlassScriptPhysician profile
Timothy S Daly
NPI 1699815977
$31,480.42
in general payments reported to CMS, 2019-2025
32 companies · $8,899 in 2025
The $8,899 reported for 2025 was more than what 88% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,105 · 2020: $2,924 · 2021: $3,636 · 2022: $4,584 · 2023: $1,039 · 2024: $6,292 · 2025: $8,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,750 · Food and Beverage: $6,149 · Travel and Lodging: $3,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,750.00 |
| Food and Beverage | $6,149.33 |
| Travel and Lodging | $3,331.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18,909.27 | 2019-2025 | Lifevest |
| Penumbra, INC. | $4,685.59 | 2021-2025 | Indigo System, Penumbra System |
| Medtronic, INC. | $3,221.41 | 2022-2025 | Symplicity G3, Micra, Mycarelink |
| Amgen INC. | $766.66 | 2019-2025 | Repatha |
| Shockwave Medical, INC | $736.46 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $507.49 | 2021-2025 | Impella |
| Sanofi-Aventis U.S. LLC | $343.00 | 2019-2023 | |
| Abbott Laboratories | $316.57 | 2020-2023 | Mitraclip |
| Astrazeneca Pharmaceuticals LP | $255.54 | 2020-2021 | |
| Atricure, INC. | $221.86 | 2021-2024 | |
| Boston Scientific Corporation | $163.83 | 2022-2025 | Avvigo Guidance System, Rotapro, Guidezilla |
| Novartis Pharmaceuticals Corporation | $153.61 | 2019-2024 | |
| Esperion Therapeutics, INC. | $147.51 | 2020-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.53 | 2019-2023 | Jardiance |
| Kestra Medical Technology Services, INC. | $124.65 | 2022-2025 | Assure Wcd |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $118.98 | 2019 | |
| Amarin Pharma, INC. | $90.00 | 2020 | |
| Edwards Lifesciences Corporation | $86.84 | 2022 | |
| Janssen Pharmaceuticals, INC | $81.46 | 2019-2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $71.73 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $61.76 | 2019-2025 | Eliquis |
| Actelion Pharmaceuticals US, INC. | $55.06 | 2021-2022 | |
| Pfizer INC. | $45.53 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $29.12 | 2021-2022 | |
| Cardiovascular Systems INC. | $28.19 | 2019 | |
| Impulse Dynamics (USA) INC. | $23.16 | 2022 | |
| Novo Nordisk INC | $20.74 | 2023 | Rybelsus, Ozempic |
| Kiniksa Pharmaceuticals International, Plc | $17.61 | 2024 | Arcalyst |
| Vifor Pharma, INC. | $15.64 | 2019 | |
| Philips North America LLC | $13.39 | 2019 | |
| Irhythm Technologies, INC. | $12.66 | 2022 | |
| Gilead Sciences, INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.